Conference: “Inhibidores en CDK4/6 en cáncer de mama: eligiendo el mejor”
Three experts on oncology will talk about the convenience and efficiency of opting for one of the three cyclin inhibitors that are currently used to treat breast cancer: ribociclib, abemaciclib and palbociclib. During the debate, there will be a questionnaire to know the attendees' perception of the different treatments. At the end of the debate there will be a round of questions.
The debate will be given by Maria Bidal, from Hospital Clínic-IDIBAPS; Meritxell Bellet, from the Vall d'Hebron Barcelona University Campus, and Mireia Margelí, from ICO Badalona-B·ARGO. It will be chaired by ALeix Prat, director of the Innovation Chair on Precision Oncology of the UB and head of the Department of Medical Oncology of the Hospital Clínic-IDIBAPS.